Affymax and Takeda Report Positive Phase II Data for Anemia Drug
Posted on: Monday, 12 May 2008, 09:01 CDT
Takeda Global R&D Center and Affymax have reported positive 12 month data from their ongoing Phase II trial evaluating the safety and tolerability of Hematide, an investigational drug in development for the treatment of anemia associated with chronic kidney disease.
Preliminary data from the trial showed that Hematide administered once every four weeks was well tolerated and maintained mean hemoglobin levels between 11 and 12g/dL in patients with chronic kidney disease (CKD), both pre-dialysis and hemodialysis, over a 12 month period.
In addition, the companies have announced the results of two other studies. One study also assessed safety and tolerability of Hematide in CKD, but only for patients already on hemodialysis and a third presentation detailed data relating to the treatment with Hematide of CKD patients with pure red cell aplasia (PRCA), a rare but serious condition, where the body produces antibodies to erythropoiesis stimulating agents (ESAs) and the patient's endogenous erythropoietin. Patients who develop PRCA are usually transfusion-dependent. In this study, treatment of these patients with Hematide resulted in maintenance of hemoglobin levels within target in the absence of transfusions.
Andrzej Wiecek, trial investigator, said: "We are pleased that these trials show the potential for Hematide to be dosed on a once-monthly basis while maintaining stable hemoglobin levels."
Source: Datamonitor
Related Articles
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance
- MedcomSoft Clinical Data Repository Offers Access to Nation's Only Homogeneous Coding of All Point-of-Care Clinical Patient Data
- Legislation Promotes Healthcare IT Infrastructure and Patient Data Safety Across Europe
- GE Healthcare Receives FDA Clearance for CARESCAPE Patient Data Module for Mobile Patient Monitoring
- Affymax(R) Announces Results From Phase 2 Clinical Trial of Hematide(TM) for the Treatment of Anemia in Dialysis Patients
- Interim Data Suggest Potential Benefits of Aranesp(R) Dosed Every Three Weeks With Intravenous Iron for Chemotherapy-Induced Anemia; 94 Percent of Patients Achieved Target Hemoglobin Level
- NEC Extends Patient Data Management Capabilities for Healthcare Providers
- Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients With Myelodysplastic Syndrome (MDS); Patients With Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue
- Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglobin Levels in Patients With Chemotherapy-Induced Anemia
 |
 |
User Comments (0)
RSS Feeds